• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 31, 2022

View Archived Issues
finance-dollar-growth.png

Billiontoone’s $125M series C shows viability of big rounds in prenatal testing

Just nine months after a $55 million series B fundraising round, Billiontoone Inc. delivered an oversubscribed series C of $125 million. Demand for the company’s Unity prenatal test, which can assess fetal risk for common recessive conditions and aneuploidies using one maternal blood sample, tripled over the last year. Read More

Securities fraud class actions still a source of cost for life science companies

Publicly traded companies in the life sciences face a number of sources of litigation, including lawsuits over alleged securities fraud, and a new report by Dechert LLP highlights a diminishing number of such lawsuits across the U.S. economy. However, the proportion of such lawsuits directed at drug and device makers has not diminished, making clear that companies in the life sciences must tread carefully when disclosing information such as the status of products in development for fear that a perceived misrepresentation could spark expensive and time-consuming litigation. Read More
Courts2.png

US SEC proposal may retract SPAC space

The U.S. SEC is proposing rules that could close off the advantages of going public via a special purpose acquisition company, or SPAC. Read More

Novel metabolic biomarker predicts Parkinson’s disease from an early stage

A research team from the Grenoble Institute for Neuroscience (GIN) recently discovered a blood biomarker capable of detecting the onset of Parkinson's disease (PD) from a very early stage. This discovery represents the findings of a multi-model, translational study published in the Journal of Clinical Investigation. Read More
03-31-Baymatob

Baymatob completes series A funding to bring life-saving labor-monitoring device to the clinic

Following a traumatic birth experience with her second child, Baymatob Ltd. Founder and engineer Sarah McDonald felt she had a moral obligation to do something to help women, and she developed a wearable device that uses artificial intelligence (AI) to identify mothers during labor who are at high risk of developing abnormal postpartum hemorrhage (PPH) well before giving birth.  Read More
sleep-apnea-mask-CPAP.png

USPSTF may hit snooze button on sleep apnea screening for asymptomatic patients

The U.S. Preventive Services Task Force (USPSTF) has decided to consider the merits of screening for obstructive sleep apnea (OSA), a condition thought to contribute significantly to the onset of heart disease. Even though five years have passed since the task force considered the merits of screening for asymptomatic patients, USPSTF indicated that there is still insufficient evidence to support the proposition, citing an evidence gap that if filled could prove tremendously useful to makers of devices that diagnose and treat the condition. Read More

Appointments and advancements for March 31, 2022

New hires and promotions in the med-tech industry, including: Becton Dickinson, Channel Medsystems, Pentax Medical, Telix Pharmaceuticals. Read More

Financings for March 31, 2022

Med-tech firms raising money in public or private financings, including: 4C Medical, Microport. Read More

In the clinic for March 31, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Smith+Nephew. Read More

Other news to note for March 31, 2022

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Fresnenius, Ivenix, Labcorp, Medidata, Mainz Biomed. Read More

Regulatory actions for March 31, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Edwards. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • Scientific figure illustrating astrocytes and neuron synapse

    Glia 2025: Microglial crosstalk could be early Alzheimer’s targeting opportunity

    BioWorld
    “Loss of synapses and dysfunctional synapses in a region-specific way is important in Alzheimer’s. It’s actually the strongest correlate of cognitive decline, far...
  • New oral BRD4 inhibitor blocks pathogenic expansion of epithelial progenitors in IPF models

    BioWorld Science
    Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited treatment options. IPF is thought to result from repeated microinjuries...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe